Market Overview:
The global ornithine transcarbamylase deficiency treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of ornithine transcarbamylase deficiency, rising awareness about the disease, and growing demand for better treatment options. The global ornithine transcarbamylase deficiency treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into oral and intravenous treatments. The oral treatments segment dominates this market owing to its ease of use and lower cost as compared to other treatments options available in this market. On the basis of application, hospitals pharmacies account for a major share in this market due to increased adoption rates for better patient outcomes across hospitals globally.
Product Definition:
Ornithine transcarbamylase deficiency (OTCD) is a rare autosomal recessive disorder that results in the accumulation of ammonia in the blood. OTCD is caused by a defect in the gene that codes for ornithine transcarbamylase, an enzyme responsible for converting Ornithine and carbamoyl phosphate into citrulline. The lack of this enzyme leads to a build-up of ammonia, which can cause brain damage and death if left untreated. Ornithine Transcarbamylase Deficiency Treatment is used to help remove excess ammonia from the blood and prevent further damage to the brain.
Oral:
Ornithine transcarbamylase (OTC) deficiency is an autosomal recessive metabolic disorder, which causes liver failure at an early stage. The disease has two forms: non-pathological and pathological. Pathological form of the disease is rare as compared to the non-pathological one.
Intravenous:
Intravenous (IV) is a route of administration by which drugs are administered into the body. It is generally used for the delivery of drugs and fluids into the blood vessels, lymph, or other tissues. Intravenous catheters are used to inject substances directly into a vein.
Application Insights:
Based on application, the global ornithine transcarbamylase deficiency treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacy segment held the largest share of over 40% in 2017. Rising prevalence of chronic diseases such as cardiovascular disorders, cancer, and diabetes has led to an increase in demand for Ornithine Transcarbamylase (OTC) drugs that are used for the treatment of these diseases. This trend is expected to continue over the forecast period due to increasing healthcare costs along with a rise in incidences of chronic conditions across various regions including North America and Europe.
The hospital pharmacy segment is anticipated to witness lucrative growth during the forecast period owing to rising awareness about OTC medicines among patients visiting hospitals or medical clinics for diagnosis or treatment purposes.
Regional Analysis:
North America dominated the global ornithine transcarbamylase deficiency treatment market in 2017. This is due to the high prevalence of this rare disease coupled with increasing healthcare expenditure and awareness about Ornithine Transcarbamylase (OTC) drugs. Moreover, presence of key players such as Pfizer, Inc.; Mylan N.V.; and Sanofi are also contributing towards market growth in North America region.
The Asia Pacific has one of the highest rates of child mortality worldwide; approximately 330 thousand children die annually before reaching five years old (UNICEF).
Growth Factors:
- Increasing prevalence of Ornithine Transcarbamylase Deficiency Treatment across the globe.
- Rising demand for effective and affordable Ornithine Transcarbamylase Deficiency Treatment therapies.
- Technological advancements in the field of Ornithine Transcarbamylase Deficiency Treatment research and development.
- Growing number of clinical studies on new potential therapies for Ornithine Transcarbamylase Deficiency Treatment indications being conducted worldwide
Scope Of The Report
Report Attributes
Report Details
Report Title
Ornithine Transcarbamylase Deficiency Treatment Market Research Report
By Type
Oral, Intravenous
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Abbott Laboratories, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics, Nestle, Bausch Health Companies, Ultragenyx Pharmaceutical, Arcturus Therapeutics, Acer Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Ornithine Transcarbamylase Deficiency Treatment Market Report Segments:
The global Ornithine Transcarbamylase Deficiency Treatment market is segmented on the basis of:
Types
Oral, Intravenous
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Nutricia (Danone Group)
- Mead Johnson (Reckitt Benckiser)
- Horizon Therapeutics
- Nestle
- Bausch Health Companies
- Ultragenyx Pharmaceutical
- Arcturus Therapeutics
- Acer Therapeutics
Highlights of The Ornithine Transcarbamylase Deficiency Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Intravenous
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ornithine Transcarbamylase Deficiency Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ornithine transcarbamylase deficiency is a rare genetic disorder that causes a lack of the enzyme that helps to break down proteins. This can lead to serious health problems, including liver and kidney failure, seizures, and coma. Treatment typically involves taking supplements of ornithine or other enzymes to help the body produce enough of its own protein.
Some of the major companies in the ornithine transcarbamylase deficiency treatment market are Abbott Laboratories, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser), Horizon Therapeutics, Nestle, Bausch Health Companies, Ultragenyx Pharmaceutical, Arcturus Therapeutics, Acer Therapeutics.
The ornithine transcarbamylase deficiency treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ornithine Transcarbamylase Deficiency Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ornithine Transcarbamylase Deficiency Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ornithine Transcarbamylase Deficiency Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ornithine Transcarbamylase Deficiency Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ornithine Transcarbamylase Deficiency Treatment Market Size & Forecast, 2018-2028
4.5.1 Ornithine Transcarbamylase Deficiency Treatment Market Size and Y-o-Y Growth
4.5.2 Ornithine Transcarbamylase Deficiency Treatment Market Absolute $ Opportunity
Chapter 5 Global Ornithine Transcarbamylase Deficiency Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Type
5.2.1 Oral
5.2.2 Intravenous
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ornithine Transcarbamylase Deficiency Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ornithine Transcarbamylase Deficiency Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ornithine Transcarbamylase Deficiency Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Type
9.6.1 Oral
9.6.2 Intravenous
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ornithine Transcarbamylase Deficiency Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Type
10.6.1 Oral
10.6.2 Intravenous
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ornithine Transcarbamylase Deficiency Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Type
11.6.1 Oral
11.6.2 Intravenous
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ornithine Transcarbamylase Deficiency Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Type
12.6.1 Oral
12.6.2 Intravenous
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ornithine Transcarbamylase Deficiency Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Type
13.6.1 Oral
13.6.2 Intravenous
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ornithine Transcarbamylase Deficiency Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ornithine Transcarbamylase Deficiency Treatment Market: Competitive Dashboard
14.2 Global Ornithine Transcarbamylase Deficiency Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Nutricia (Danone Group)
14.3.3 Mead Johnson (Reckitt Benckiser)
14.3.4 Horizon Therapeutics
14.3.5 Nestle
14.3.6 Bausch Health Companies
14.3.7 Ultragenyx Pharmaceutical
14.3.8 Arcturus Therapeutics
14.3.9 Acer Therapeutics
